



Novel ACTN1 variants in cases of thrombocytopenia

Anne Vincenot, Paul Saultier, Shinji Kunishima, Marjorie Poggi,
Marie-Françoise Hurtaud-Roux, Alain Roussel, Christine Biron-Andreani,
Jean-François Claisse, Remy Dulery, Eric Durot, et al.

► To cite this version:

Anne Vincenot, Paul Saultier, Shinji Kunishima, Marjorie Poggi, Marie-Françoise Hurtaud-Roux, et al.. Novel ACTN1 variants in cases of thrombocytopenia. Human Mutation, 2019, 40 (12), pp.2258-2269. 10.1002/humu.23840 . hal-02556150

HAL Id: hal-02556150

<https://amu.hal.science/hal-02556150>


Submitted on 27 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.









Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0
International License



RESEARCH ARTICLE

Novel *ACTN1* variants in cases of thrombocytopenia

Anne Vincenot¹  | Paul Saultier²  | Shinji Kunishima³  | Marjorie Poggi²  |
 Marie-Françoise Hurtaud-Roux¹ | Alain Roussel⁴  | *ACTN1* study coinvestigators* |
 Nicole Schlegel¹ | Marie-Christine Alessi^{2,5} 

¹CHU Robert Debré, National Reference Center for Inherited Platelet Disorders and Biological Hematology Service, AP-HP, Paris, France

²Aix-Marseille Univ, INSERM, INRA, C2VN, Marseille, France

³Department of Medical Technology, Gifu University of Medical Science, Seki, Gifu, Japan

⁴Aix Marseille University, CNRS, AFMB, Marseille, France

⁵APHM, CHU Timone, French Reference Center for Inherited Platelet Disorders, Marseille, France

Correspondence

Marjorie Poggi, C2VN Laboratory, UMR Inserm 1062/INRA 1260/Aix Marseille University, Faculté de Médecine Timone, 27 Boulevard Jean Moulin, 13385 Marseille, France.
 Email: marjorie.poggi@univ-amu.fr

Funding information

Fondation pour la Recherche Médicale, Grant/Award Number: P.Saultier/FDM20150633607; Assistance Publique-Hôpitaux de Paris, Grant/Award Number: DRCD number P070110

Abstract

The *ACTN1* gene has been implicated in inherited macrothrombocytopenia. To decipher the spectrum of variants and phenotype of *ACTN1*-related thrombocytopenia, we sequenced the *ACTN1* gene in 272 cases of unexplained chronic or familial thrombocytopenia. We identified 15 rare, monoallelic, nonsynonymous and likely pathogenic *ACTN1* variants in 20 index cases from 20 unrelated families. Thirty-one family members exhibited thrombocytopenia. Targeted sequencing was carried out on 12 affected relatives, which confirmed presence of the variant. Twenty-eight of 32 cases with monoallelic *ACTN1* variants had mild to no bleeding complications. Eleven cases harbored 11 different unreported *ACTN1* variants that were monoallelic and likely pathogenic. Nine variants were located in the α -actinin-1 (*ACTN1*) rod domain and were predicted to hinder dimer formation. These variants displayed a smaller increase in platelet size compared with variants located outside the rod domain. In vitro expression of the new *ACTN1* variants induced actin network disorganization and led to increased thickness of actin fibers. These findings expand the repertoire of *ACTN1* variants associated with thrombocytopenia and highlight the high frequency of *ACTN1*-related thrombocytopenia cases. The rod domain, like other *ACTN1* functional domains, may be mutated resulting in actin disorganization in vitro and thrombocytopenia with normal platelet size in most cases.

KEYWORDS

actin, actinin, *ACTN1*, constitutional, platelet, rod domain, thrombocytopenia

1 | INTRODUCTION

Inherited thrombocytopenia comprises a group of rare and genetically heterogeneous diseases that are sometimes difficult to distinguish from acquired thrombocytopenia (Nurden, Freson, & Seligsohn, 2012). As a result, diagnosis of the disease is often delayed, and patients may receive inappropriate treatment. Pathogenic variants of the *ACTN1* gene, which encodes α -actinin-1 (*ACTN1*) protein, have recently been reported to

cause *ACTN1*-related thrombocytopenia (*ACTN1*-RT) (MIM #102575) (Bottega et al., 2015; Boutroux et al., 2017; Guéguen et al., 2013; Kunishima et al., 2013; Westbury, Shoemark, & Mumford, 2017; Yasutomi et al., 2016). *ACTN1*-RT is one of the most frequent forms of inherited thrombocytopenia (4.2–5.6%) and is characterized by irregular mild bleeding and slightly increased mean platelet volume (Bottega et al., 2015; Faleschini et al., 2018).

ACTN1 is an antiparallel, dimeric, actin cross-linking protein composed of three domains: the N-terminal actin-binding (AB) domain composed of two calponin homology domains; the C-terminal calmodulin (CaM) domain, which binds another actinin molecule, and the central rod

**ACTN1* study coinvestigators are listed in the Appendix.

domain composed of four spectrin-like repeats (SRs) (Gimona & Mital, 1998; Murphy, Lindsay, McCaffrey, Djinić-Carugo, & Young, 2016; Sjöblom, Salmazo, & Djinić-Carugo, 2008). Twenty-five ACTN1 variants have been described so far, of which 16 have been shown to alter the AB and CaM domains (Bottega et al., 2015; Faleschini et al., 2018; Guéguen et al., 2013; Kunishima et al., 2013) and induce varying degrees of actin network disorganization, while four variants were localized in the neck domains flanking the rod domain (Bottega et al., 2015; Kunishima et al., 2013). Variants in the AB domain have been demonstrated to induce increased ACTN1 binding to actin filaments (Murphy et al., 2016). However, functional data on variants affecting the rod domain are scarce. Only one variant p.(Leu395Gln) has been identified in the second SR of the rod domain. This variant was associated in vitro with disorganized, thicker, and shorter actin filaments (Yasutomi et al., 2016). Using cluster-based analysis of high-throughput sequencing data, the Bridge Consortium has described four novel ACTN1 rod domain variants: p.(Arg320Gln), p.(Ala425Thr), p.(Leu547Pro), p.(Ala587Val) associated with macrothrombocytopenia and mild to no bleeding (Westbury et al., 2015). However, a functional study was not performed.

To better define the spectrum of ACTN1 gene variants and the ACTN1-RT phenotype, we sequenced the ACTN1 gene in cases of unexplained constitutional thrombocytopenia. We identified 15 different ACTN1 variants associated with constitutional thrombocytopenia, including 11 novel genetic variants. This report describes the largest set of novel ACTN1 variants to date. In this study, we focused on nine of the new variants associated with alterations in the rod domain, thereby providing new insight into the role that the rod domain plays in ACTN1-RT.

2 | PATIENTS AND METHODS

2.1 | Patients

From 2009 to 2017, we recruited 272 unrelated probands with inherited thrombocytopenia of unknown origin. Genetic analyses were performed at the French Reference Center for Inherited Platelet Disorders at Robert Debré University Hospital in Paris ($n = 166$) and at La Timone University Hospital in Marseille ($n = 106$). Relatives of ACTN1 variant carriers were also included in the study when possible.

Medical and family history data were obtained from medical reports and patient interviews. Bleeding tendency was evaluated according to the World Health Organization (WHO) bleeding score: grade 0, no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; and grade 4, debilitating blood loss.

All cases were included after obtaining informed written consent in accordance with protocols approved by local institutional review boards and the Declaration of Helsinki principles.

2.2 | Screening and prediction of variant pathogenicity

Genomic DNA was extracted from peripheral blood samples and used to screen the ACTN1 gene (NG_029480.1). Targeted ACTN1 DNA

sequence analysis was performed on samples from 97 cases with MYH9-negative thrombocytopenia, and targeted multigene sequencing was carried out on samples from 69 cases in Paris (50-gene panel) and 106 cases in Marseille (308-gene panel) (Saultier et al., 2017). The variants identified via gene-panel sequencing were confirmed by targeted ACTN1 DNA sequence analysis. When an ACTN1 variant was identified via targeted ACTN1 DNA sequence analysis, the DNA sample was also analyzed using the 50-gene panel to exclude the presence of other pathological variants. The multigene panels used are described in the Supporting Information data file. Once a variant was discovered, available samples from family members were tested for the variant using targeted ACTN1 sequencing. We denoted novel variants as those that were either absent or present at a very low level ($<0.1\%$) in public variant repositories and the functional impact of each variant was predicted using various algorithms (Supplemental data file).

Nomenclature: All variants are described according to HGVS guidelines (<http://varnomen.hgvs.org/bg-material/refseq/>) numbering the A of the initiation methionine as +1 in reference sequence NM_001130004.1 and the corresponding amino acid as +1 in reference sequence NP_001123476.

Molecular modeling was carried out to predict modifications caused by the variants using PyMOL software (PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC) and the crystal structure of actinin isoform 2 (ACTN2, PDB code 4D1E). ACTN2 sequence alignment revealed a highly conserved sequence with 81.4% identity (without considering signal peptides and the large insertion from the ACTN1 residues 752–790). Therefore, ACTN2 is a good template to construct the ACTN1 structural model (Ribeiro et al., 2014).

2.3 | Site-directed mutagenesis

The wild-type ACTN1 gene corresponded to a full-length ACTN1 sequence from normal platelet complementary DNA (cDNA) subcloned in a pCDNA3.1-N-Myc plasmid as previously described (Kunishima et al., 2013). Site-directed mutagenesis of the human expression plasmid pCDNA3.1-ACTN1-N-Myc was performed using a GeneArt Site-Directed Mutagenesis System (Thermo Fisher Scientific) according to the manufacturer's instructions. The primer sequences are available upon request. Mutagenesis efficiency was confirmed by sequencing (Beckman Coulter Genomics).

2.4 | Immunofluorescence analysis

The pathogenic consequence of each new ACTN1 variant on actin structure was assessed using immunofluorescence in CHO cells transiently transfected with wild-type or ACTN1 variant constructs (PolyJet In Vitro DNA Transfection Reagent, SignaGen Laboratories). Briefly, CHO cells were cultured in F12 Nutrient Mixture supplemented with 10% fetal bovine serum in glass coverslips coated with fibronectin (2 $\mu\text{g}/\text{ml}$). Forty-eight hours after transfection, the cells were fixed with 1% paraformaldehyde for 10 min, permeabilized with 0.3% triton X-100 in phosphate-buffered saline (PBS) for 5 min, and blocked using 3% bovine serum albumin in PBS for 30 min. The cells

were labeled using anti-c-Myc antibody (Santa Cruz), followed by incubation with Alexa 546-labeled goat antirabbit IgG (Life Technologies A11010) and Alexa 488-conjugated phalloidin (Life Technologies 12379). After washing the cells, the slides were mounted with DAPI Fluoromount (Southern Biotech), and images were obtained using an AXIO Imager M1 microscope (Carl Zeiss, Germany). Actin fibers were examined using the “analyze particle” plugin of the ImageJ program. Six 100-pixel square areas with the greatest density of actin fibers were analyzed to determine the feret diameter of the actin fibers. Two to three cells were analyzed for each condition. Low levels of fluorescent signal attributed to low-level autofluorescence and background noise were corrected using a 9.75% threshold value. The intergroup difference was evaluated using one-way analysis of variance (ANOVA) with Dunnett's posthoc test.

2.5 | Blood cell analysis

Platelet count was measured on venipuncture ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood samples using an automated cell counter. Blood smears were stained with May-Grünwald-Giemsa stain. Mean platelet diameter (MPD) was measured on peripheral blood films using optical microscopy and software-assisted image analysis (Calopix, TRIBVN Healthcare, Châtillon, France) as previously described (Saposnik et al., 2014). The reference ranges for platelet count and diameter were $155\text{--}394 \times 10^9 \text{ L}^{-1}$ and $1.9\text{--}2.9 \mu\text{m}$, respectively, as defined by the 2.5–97.5 percentile range of the control population ($n = 64$ for platelet count and $n = 92$ for platelet diameter).

2.6 | Statistical analyses

Quantitative variables are expressed as the mean \pm standard error of the mean. The intergroup difference was evaluated using an unpaired *t* test or one-way ANOVA with Dunnett's posthoc test. The $p < 0.05$ was considered as significant.

3 | RESULTS

3.1 | Identification of novel ACTN1 variants

Targeted DNA sequence analysis and gene-panel sequencing of the ACTN1 gene were carried out on samples derived from 272 cases with suspected inherited thrombocytopenia: 97 cases with MYH9-negative thrombocytopenia and 175 cases with thrombocytopenia of unknown origin.

We identified 15 different monoallelic and nonsynonymous ACTN1 variants, which were likely pathogenic, in 20 index cases (Figure 1 and Table 1). Gene-panel sequencing did not reveal potentially pathogenic variants in other genes among the carriers of ACTN1 variants nor other ACTN1 variants.

Four of these variants, which have been associated with ACTN1-RT in previous studies (Bottega et al., 2015; Guéguen et al., 2013; Kunishima et al., 2013), were detected in nine families (Families 1–9:

c.136C>T: p.(Arg46Trp); c.137G>A: p.(Arg46Gln); c.313G>A: p.(Val105Ile); and c.2212C>T: p.(Arg738Trp) (Figure 1).

The 11 remaining variants (Families 10–20) were novel and corresponded to single amino acid substitutions primarily located in the SR domains: c.770C>G: p.(Thr257Arg); c.970A>G: p.(Lys324Glu); c.982G>A: p.(Val328Met); c.986A>G: p.(Gln329Arg); c.1193A>C: p.(Lys398Thr); c.1295C>T: p.(Ala432Val); c.1348C>T: p.(Arg450Cys); c.1349G>A: p.(Arg450His); c.1864C>T: p.(His622Tyr); and c.2243T>A: p.(Met748Lys) (Figure 1). We found two variants located in the SR4 domain (c.[2156A>C; 2157G>C]) in Family 19. These two variants were also found in the mother of the proband, thus indicating that the two variants are probably located on the same ACTN1 allele, resulting in a p.(Glu719Pro) amino acid substitution (Figure 1).

All new variants were absent from the dbSNP, ExAC and gnomAD databases (Table 1). Some of these variants (p.(Thr257Arg), p.(Lys398Thr), p.(Arg450Cys), p.(Arg450His), p.(Gln719Pro), and p.(Met748Lys)) were found in seven relatives of six different families (Families 10, 14, 16, 17, 19, and 20) and were associated with thrombocytopenia (Figure 1a and Table 2). This finding reveals a strong probability of association with dominant inheritance.


3.2 | Bleeding diathesis

Among the 32 affected patients (probandi and relatives), 18 were female and 14 were male. Most index cases were diagnosed during adolescence or young adulthood (Table 2), at a mean age of 25.9 years (9–66 years). For each case, thrombocytopenia was identified incidentally during a blood cell count and outside any bleeding episode. None of the patients were diagnosed with immune thrombocytopenia. Patient examinations did not reveal any phenotypic abnormalities that may be associated with ACTN1 variants. Bleeding diathesis was absent in 22 patients and mild in six patients, consisting of either epistaxis, subcutaneous hemorrhage, or prolonged bleeding after surgery. Four of 13 patients who underwent at least one surgical procedure experienced bleeding after surgery, and severe bleeding was reported in two patients (WHO bleeding score = 3; Figure 2a and Table 2). Eight women gave birth to a total of 13 children without excessive bleeding reported. All patients displayed normal hemoglobin values and leukocyte counts (data not shown).

3.3 | Platelet characteristics

Thrombocytopenia was moderate in the patient cohort (mean platelet count: $88 \times 10^9 \text{ L}^{-1}$ [range $39\text{--}135 \times 10^9 \text{ L}^{-1}$]). Twelve (37.5%) of the 32 patients had a mean platelet count below $80 \times 10^9 \text{ L}^{-1}$. Only two patients had a mean platelet count below $50 \times 10^9 \text{ L}^{-1}$ (Table 2). Patient blood smears did not reveal platelet poikilocytosis. Platelet counts did not differ between carriers of rod and nonrod domain variants (Figure 2b).

(a)



(b)




FIGURE 1 Identification and characterization of novel ACTN1 variants. (a) Pedigrees of the affected families. Squares denote males, and circles denote females. Black filled, and empty symbols represent thrombocytopenic and nonthrombocytopenic family members, respectively. Dotted-line symbols were used when platelet count was unavailable. ACTN1 gene constitutional variant status is indicated at the top of symbols representing family members. All identified variants were monoallelic. (b) Structural domains of ACTN1 and localization of ACTN1 variants: (i) previously described with proven functional impact (dark), (ii) previously described but untested for functional impact (gray), (iii) previously described with proven functional impact and reported here (green), and (iv) previously undescribed and reported here (red). The four SRs form the rod domain of the protein. CaM, calmodulin-like domain; CH, calponin homology domain; SR, spectrin repeat

Overall, platelet diameter values were increased in carriers of ACTN1 variants. Fifteen (62.5%) of the 24 patients tested had a platelet diameter $\geq 2.9 \mu\text{m}$ (97.5th percentile of the control values). However, carriers of variants in the rod domain displayed platelets of smaller diameter compared with carriers of variants outside the rod domain ($2.79 \pm 0.28 \mu\text{m}$ vs. $3.11 \pm 0.33 \mu\text{m}$

$p = .026$) (Figure 2c). This intergroup difference was even greater after merging MPD data from the present study with data from previously reported ACTN1 variant carriers ($-0.5 \mu\text{m}$; $p < .01$; $n = 54$; Figure S1), thereby indicating that some patients with ACTN1-RT may not have large platelets, especially if the variant is localized in the rod domain.

TABLE 1 ACTN1 variants identified

Mutation (cDNA)	VEP consequence	Exon	Protein effect	Bioinformatics analysis					Allele frequency (%)				In vitro actin fibers disorganization	ClinVar	Variants classification (ACMG)	References
				Poly	SIFT	Provean	Mutation Taster	PhastCons	CADD score	1000G	ExAc	dbSNP				
c.136C>T	Missense	2	p.(Arg46Trp)	D	D	D	D	1	35	0	0.00081	NA (rs747559032)	Yes	NA	Likely pathogenic	Bottega et al. (2015)
c.137G>A	Missense	2	p.(Arg46Gln)	D	D	D	D	1	35	0	0	NA (rs387907348)	Yes	Pathogenic	Likely pathogenic	Kunishima et al. (2013)
c.313G>A	Missense	2	p.(Val105Ile)	D	D	B	D	1	34	0	0	NA (rs387907345)	Yes	Pathogenic	Likely pathogenic	Kunishima et al. (2013)
c.2212C>T	Missense	18	p.(Arg738Trp)	B	D	D	D	1	35	0	0	NA (rs387907349)	Yes	Pathogenic	Likely pathogenic	Kunishima et al. (2013)
c.770C>G	Missense	9	p.(Thr257Arg)	D	D	D	D	1	28.6	0	0	0	Yes	NA	Likely pathogenic	This study
c.970A>G	Missense	10	p.(Lys324Glu)	D	D	D	D	1	28.6	0	0	0	Yes	NA	Likely pathogenic	This study
c.982G>A	Missense	10	p.(Val328Met)	D	D	B	D	1	26.8	0	0	0	Yes	NA	Likely pathogenic	This study
c.986A>G	Missense	10	p.(Gln329Arg)	B	D	B	D	1	26.4	0	0	0	Yes	NA	Likely pathogenic	This study
c.1193A>C	Missense	11	p.(Lys398Thr)	D	D	D	D	1	29.8	0	0	0	Yes	NA	Likely pathogenic	This study
c.1295C>T	Missense	12	p.(Ala432Val)	D	D	D	D	1	34	0	0	0	Yes	NA	Likely pathogenic	This study
c.1348C>T	Missense	12	p.(Arg450Cys)	D	D	D	D	1	35	0	0	0	Yes	NA	Likely pathogenic	This study
c.1349G>A	Missense	12	p.(Arg450His)	D	D	D	D	1	35	0	0	0	Yes	NA	Likely pathogenic	This study
c.1864C>T	Missense	16	p.(His622Tyr)	D	D	B	D	1	20.9	0	0	0	Yes	NA	Likely pathogenic	This study
c.[2156A>C; 2157G>C]	Missense	18	p.(Gln719Pro)	D	D	D	D	1	25.7	0	0	0	Yes	NA	Likely pathogenic	This study
c.2243T>A	Missense	18	p.(Met748Lys)	D	D	D	D	1	24.8	0	0	0	Yes	NA	Likely pathogenic	This study

Note: The consequences of variations were analyzed using VEP (<http://www.ensembl.org/Tools/VEP>). The effect on the protein's function was analyzed using several bioinformatics tools (PolyPhen-2, SIFT, Mutation Taster, PhastCons, and CADD scores). A PhastCons score of 1 reflects a total conservation of the residue among species, indicating then a probably pathogenic alteration. A scaled CADD score (<http://cadd.gs.washington.edu/score>) of 20 means that a variant is amongst the top 1% of deleterious variants in the human genome, while a score of 30 means that the variant is in the top 0.1%. The in-population allele frequencies were derived from 1000 Genomes Project (1000G) and ExAc databases.

Abbreviations: B, benign, D, damaging, NA, not available; VEP, variant effect predictor.

TABLE 2 Clinical and biological characteristics of families with *ACTN1* variants

Family	Patient	Age at diagnosis (year)	WHO BS	Platelet count ($\times 10^9/l$)	MPD (μm)	<i>ACTN1</i> variant
1	I 2	20	0	39	3.1	p.(Arg46Trp)
	II 1	1	0	54	2.8	p.(Arg46Trp)
	II 2	0	0	NA	2.7	p.(Arg46Trp)
2	II 1	29	0	54	3.0	p.(Arg46Trp)
	II 2	27	0	76	3.2	p.(Arg46Trp)
3	I 2	32	3	90	4.0	p.(Arg46Trp)
4	II 2	18	0	95	3.4	p.(Arg46Trp)
5	II 1	11	0	104	2.9	p.(Arg46Gln)
6	I 2	16	0	86	2.7	p.(Val105Ile)
	II 1	19	1	87	3.0	p.(Val105Ile)
	II 2	0	0	106	3.2	p.(Val105Ile)
7	II 1	15	1	80	3.5	p.(Arg738Trp)
8	III 1	18	2	95	3.0	p.(Arg738Trp)
9	II 2	13	0	45	NA	p.(Arg738Trp)
10	I 1	66	0	72	NA	p.(Thr257Arg)
	II 1	43	0	120	NA	p.(Thr257Arg)
	II 2	35	0	135	NA	p.(Thr257Arg)
11	II 2	NA	0	70	NA	p.(Lys324Glu)
12	II 1	18	0	114	2.7	p.(Val328Met)
13	II 3	31	0	124	2.9	p.(Gln329Arg)
14	I 2	NA	0	137	NA	p.(Lys398Thr)
	II 1	28	2	124	2.5	p.(Lys398Thr)
15	III 1	23	0	94	2.8	p.(Ala432Val)
16	II 2	48	0	51	2.8	p.(Arg450Cys)
	III 1	20	0	99	3.2	p.(Arg450Cys)
17	I 1	NA	0	NA	NA	p.(Arg450His)
	II 1	NA	0	140	2.5	p.(Arg450His)
18	II 1	48	3	78	3.2	p.(His622Tyr)
19	I 2	NA	0	65	NA	p.(Gln719Pro)
	II 1	9	0	78	2.5	p.(Gln719Pro)
20	I 2	23	1	74	3.1	p.(Met748Lys)
	II 1	9	0	95	3.0	p.(Met748Lys)

Note: The cases are annotated with the identifiers described in Figure 1a. WHO BS: grade 0, no bleeding; grade 1, cutaneous bleeding only; grade 2, mild blood loss; grade 3, gross blood loss, requiring transfusion; and grade 4, debilitating blood loss, retinal or cerebral, associated with fatality. The platelet count value provided for each patient represents the mean of all platelet counts available for that patient. The reference ranges for platelet count and diameter were $155\text{--}394 \times 10^9 \text{ L}^{-1}$ and $1.9\text{--}2.9 \mu m$, respectively, as defined by the 2.5–97.5 percentile range of the control population ($n = 64$ for platelet count and $n = 92$ for platelet diameter).

Abbreviations: MPD: mean platelet diameter; ND, not determined; WHO BS, World Health Organization Bleeding Score.

3.4 | In silico protein prediction analysis

Eight new variants were predicted as pathogenic using the six *in silico* prediction algorithms (Table 1).

All new variants involved residues that are highly conserved in *ACTN1* orthologs in nine distantly-related species (Table 3); all variants also had a PhastCons score of 1. The CADD scores were high, ranging from 20.9 to 35 (Table 1), within the top 1% of deleterious variants genomewide (Kircher et al., 2014), assuming the deleterious nature of the variants. We obtained conflicting

prediction results for the variants c.986A>G: p.(Gln329Arg) (predicted as pathogenic using the Sift, PROVEAN and Mutation Taster algorithms and benign using the Polyphen-2 algorithm) as well as c.982G>A: p.(Val328Met) and c.986A>G: p.(Gln329Arg) (both predicted as pathogenic using the Polyphen-2, Sift and Mutation Taster algorithms and benign using the PROVEAN algorithm). We obtained such discrepancies for the previously reported deleterious *ACTN1* variants c.2212C>T, p.(Arg738Trp) and c.313G>A:(Val105Ile).

TABLE 3 Conservation of the human ACTN1 residues Thr257, Val328, Gln329, Lys324, Lys398, Ala432, Arg450, His622, Gln719, and Met748 in orthologs

Species	UniProt ID	Residues	Identity rate (%)	
			ACTN1	Rod domain
Human	<i>Homo sapiens</i>	P12814	T257 V328 K324 Q329 K398 A432 R450 H622 Q719 M748	Reference
Chimpanzee	<i>Pan troglodytes</i>	H2RDW7	T244 V315 K311 Q316 K385 A419 R437 H609 Q706 M735	99.8
Macaque	<i>Macaca mulatta</i>	H9YUP4	T257 V328 K324 Q329 K398 A432 R450 H622 Q719 M748	99.9
Dog	<i>Canis lupus familiaris</i>	E2QY08	T257 V328 K324 Q329 K398 A432 R450 H622 Q719 M748	99.3
Cow	<i>Bos taurus</i>	Q3B7N2	T257 V328 K324 Q329 K398 A432 R450 H622 Q719 M748	99.4
Mouse	<i>Mus musculus</i>	Q7TPR4	T257 V328 K324 Q329 K398 A432 R450 H622 Q719 M748	99.2
Rat	<i>Rattus norvegicus</i>	Q6T487	T257 V328 K324 Q329 K398 A432 R450 H622 Q719 M748	99.3
Zebrafish	<i>Danio rerio</i>	B8JHU4	T267 V338 K334 Q339 K408 A442 R460 H632 Q729 M758	93.4
Xenopus	<i>Xenopus tropicalis</i>	F7B6G0	T255 V326 K322 Q327 K396 A430 R448 H620 Q717 M746	94.9

Note: The amino-acid sequence of human ACTN1 protein was compared to orthologs using Clustal OMEGA (<http://www.ebi.ac.uk/Tools/msa/clustalo/>). The novel variations reported in this study alter the residues Thr257, Val328, Lys324, Gln329, Lys398, Ala432, Arg450, His622, Gln719, and Met748. The table gives the corresponding residue in eight other species. Identity rate is provided for the entire ACTN1 sequence (penultimate column) and for the rod domain sequence (last column), showing that ACTN1 sequence and its rod domain are highly conserved between these species.




FIGURE 2 Bleeding, platelet counts and platelet diameters in ACTN1 variant carriers. (a) Characterization of bleeding phenotype in ACTN1 variant carriers. Bleeding episodes of the 30 affected patients were recorded. The cases are annotated with the identifiers described in Figure 1a. The number of patients suffering from a bleeding phenotype is reported on the left. The number of bleeding symptoms for each patient is indicated at the bottom. The type of bleeding disorder is indicated on the right. Exposure to surgery is indicated in the last line. (b,c) Platelet phenotype of ACTN1 variant carriers according to variant location (rod domain vs. nonrod domain variant): platelet count ($\times 10^9 \text{ L}^{-1}$) (b) and platelet diameter (μm) (c). Among nonrod domain ACTN1 variant carriers, those with variants in the AB domain or the AB/rod domain neck are depicted in gray and those with variants in the CaM domain or the rod domain/CaM domain neck are depicted in black. The mean \pm standard error of the mean is shown for each group. MPD values represent the mean of 200 platelet diameter values. The intergroup difference was evaluated using an unpaired *t* test. **p* < .05. The lower limit of the reference range for platelet counts ($155 \times 10^9 \text{ L}^{-1}$) and the upper limit of the reference range for platelet diameters ($2.9 \mu\text{m}$) are represented with a dotted line. ACTN1, α -actinin-1; N, no; NA, not available; ns, nonsignificant; Y, yes

The impact of the novel variants on ACTN1 structure and function was examined *in silico* using PyMOL software (Figure 3). Sequence alignment of ACTN1 and ACTN2 revealed a highly conserved sequence, enabling reliable localization of the ACTN1 variants against the ACTN2 crystal structure (PDB code 4D1E) (Ribeiro et al., 2014). The ACTN2 dimer displayed a cylindrical shape approximately 360 Å long and 60 Å wide. The antiparallel ACTN2 dimer assembled predominantly via the rod domain (SRs 1–4). Interestingly, seven variants (*i.e.*, p.(Lys324Glu), p.(Val328Met), p.(Gln329Arg), p.(Lys398Thr), p.(Ala432Val), p.(Arg450Cys), and p.(Arg450His)) were located at the dimer interface and may thus impair dimerization (Foley & Young, 2013) and cause protein instability. Protein predictions revealed that the variants p.(Arg450Cys) and p.(Arg450His) have disruptive potential, as they result in loss of a salt bridge. The variant p.(Gln719Pro) was predicted to destabilize the structure of SR4 due to the introduction of a proline residue in a helical secondary structure. Such destabilization might alter the interaction of ACTN1 with numerous structural or signaling platelet proteins such as actin, integrins, talin, or vinculin (Sjöblom et al., 2008). Finally, p.(Met748Lys), which is located on the external face

far from the dimer interface, may disrupt protein binding to partner molecules.

3.5 | Functional evaluation of variant pathogenicity

Immunofluorescence analysis of ACTN1 was performed in CHO cells. The cells transfected with wild-type ACTN1 displayed peripheral and stretched actin filaments, which were localized beneath the plasma membrane (Figure 4a), with colocalization of ACTN1 along actin filaments. By contrast, cells transfected with ACTN1 variants showed altered distribution of actin, resulting in thicker and disorganized branched fibers and cytoskeletal disorganization (Figure 4a). Actin network disorganization was quantified via image analysis using the ImageJ program after correction for autofluorescence and background noise. Mean fiber thickness was significantly increased in cells transfected with ACTN1 variants compared with wild-type ACTN1-transfected cells, with an average increase in actin fiber diameter of 1.8-fold (range, 1.4- to 2.4-fold) (Figure 4b). The same trend was observed for fiber perimeter (1.8-fold increase; range, 1.4- to 2.4-fold) and area (2.5-fold increase; range, 1.8- to 4.0-fold) (Figure 4b).




FIGURE 3 Visualization of the ACTN1 variant protein structures. The dimeric structure of ACTN2 was assembled from two halves of the ACTN2 protomer (AB domain-neck-SR1-SR2-SR3-SR4-CaM1-CaM2) through a crystallographic twofold axis. One monomer is represented as a blue surface (bottom view) and the other is shown as a yellow ribbon (top view). The two views are rotated 90° around the horizontal axis. Residues corresponding to the variants in ACTN1 are indicated in red when located at the dimer interface and in purple when located elsewhere. The upper panels correspond to close-up views of the p.(Lys324Glu), p.(Gln329Arg), p.(Val328Met), p.(Lys398Thr), p.(Arg450Cys), and p.(Ala432Val) variants. The monomer colored in blue is shown in stick representation with the residues corresponding to the variants colored in red. The other monomer is represented as a yellow surface. ACTN1, α -actinin-1; CaM, calmodulin




FIGURE 4 Novel ACTN1 variants alter ACTN1 localization and actin network organization (a) Representative immunofluorescence microscopy images of CHO cells transiently transfected with wild-type or variant ACTN1 constructs using the standard procedure. The images were visualized after ACTN1 and actin staining, as previously described (Kunishima et al., 2013). Magnification: $\times 100$. (b) Quantification of actin fiber diameter, perimeter and area. For each variant, six 100-pixel square areas with the greatest density of actin fibers were analyzed to measure the feret diameter, perimeter and area of actin fibers within two or three cells using the "analyze particle" plugin of the ImageJ program. Low levels of fluorescent signal attributed to low-level autofluorescence and background noise were corrected using a 9.75% threshold value. The intergroup difference was evaluated using one-way ANOVA with Dunnett's posthoc test. The data are shown as the mean \pm standard error of the mean. ref: reference (wild-type). $^{**}p \leq .01$, $^{***}p \leq .001$, $^{****}p \leq .0001$. ACTN1, α -actinin-1

4 | DISCUSSION

We identified 15 rare, monoallelic, non-synonymous and likely pathogenic *ACTN1* variants in 32 of 272 cases with thrombocytopenia. Eleven of the *ACTN1* variants were novel. Our assessment of this comprehensive panel of *ACTN1* variants suggests that *ACTN1*-RT is an autosomal dominant and non-syndromic inherited form of thrombocytopenia that is primarily associated with no bleeding.

The dominant pattern of disease inheritance and the association between variants and thrombocytopenia were confirmed in six families (for which segregation data was available), thus revealing an association between the indicator phenotype and presence of the variant. All novel variants were classified as pathogenic according to *in silico* analysis by at least four of six different prediction algorithms. The substituted residues were highly conserved in *ACTN1* orthologs from nine distantly related species.

Transient overexpression of *ACTN1* constructs (wild-type and variants) in cell lines is a proven method to study the effect of *ACTN1* variants on cytoskeleton organization (Bottega et al., 2015; Faleschini et al., 2018; Guéguen et al., 2013; Kunishima et al., 2013; Yasutomi et al., 2016). Some reported pathogenic variants display a deleterious effect on the actin fiber cytoskeleton, which appeared disorganized, while neutral *ACTN1* variants have no effect (Bottega et al., 2015; Faleschini et al., 2018; Kunishima et al., 2013). Analysis of actin structure showed that each of the 11 new variants exerted a pathogenic effect on actin fiber organization and size. As a result, the variants were classified as “likely pathogenic” (Class 4) according to the criteria of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (Richards et al., 2015). *ACTN1* is a bundling protein that anchors actin to a variety of intracellular structures. Recently, Murphy et al. (2016) have reported that several disease-associated variants located within the AB domain (p.(Arg46Gln), p.(Val105Ile), and p.(Glu225Lys)) cause increased binding of actinin-1 to actin filaments. We hypothesize that *ACTN1* variants induce more stable actin filaments, thereby impairing stretching and leading to shorter and thicker fibers in transfected CHO cells. Conversely, we speculate that some variants in the AB domain cause decreased binding to actin, thus leading to an unstable and disorganized actin network.

Several missense variants have previously been identified in the α -helical rod domain of various genes, which were associated with heritable diseases (Chakravarty, Chakraborti, & Chakrabarti, 2015; Fatkin et al., 1999). The central rod domain has been proposed to act as a shock absorber, a force transducer or a spacer separating the N- and C-terminal domains (Ribeiro et al., 2014) and to be the prominent protein interaction platform of *ACTN1* (Djinovic-Carugo, Gautel, Ylänne, & Young, 2002). Our *in silico* structural study shows that seven of the new variants in the rod domain may have the potential to hinder dimer formation (Foley & Young, 2013). The other variants in the rod domain may also exert protein destabilization through loss of a salt bridge or introduction of a proline residue in a helical secondary structure. These modifications may affect

rigidity and flexibility of the *ACTN1* protein and consequently of the actin fibers.

Most index cases had moderate thrombocytopenia and were incidentally diagnosed during adolescence or young adulthood. The reason why this mild phenotype is limited to platelets while *ACTN1* has a ubiquitous expression is currently not well understood. Interestingly, a restricted tissue expression profile has been also reported for variants of *ACTN4*, another isoform of actinin, that cause an inherited dominant form of a kidney disease, the focal segmental glomerulosclerosis (Kaplan et al., 2000). In a model of mouse knock-out for the *ACTN4* gene (*Actn4*^{-/-}), histological examination show abnormalities only in the kidneys (Kos et al., 2003), despite the widespread distribution of *ACTN4*.

We suppose that the presence of one wild-type *ACTN1* allele may preserve the majority of protein cell functions. Additionally, actinin isoforms have a high degree of sequence similarity (87% between *ACTN1* and *ACTN4*) and it has been showed that *ACTN1* and *ACTN4* heterodimers are the most abundant form of actinin in many cell lines (Foley & Young, 2013). Platelets express *ACTN2* and *ACTN4* (Burkhart et al., 2012), and actinin heterodimers formation has been also demonstrated in platelets (Gache, Landon, & Olomucki, 1984). Actinin paralogues homodimers, as well as heterodimers, could then share overlapping functions in cells or on the contrary have isoform-specific functions, via perhaps isoform-specific interactions with other proteins. Further experimental approaches are needed for a better understand of these mechanisms and to verify these assumptions.

Bleeding diathesis was mild or absent in patients with *ACTN1*-RT, as previously reported (Bottega et al., 2015; Faleschini et al., 2018). Nearly half of the patients ($n = 10/22$ available data) had never undergone surgery and may not have been sufficiently challenged to reveal bleeding complications. Two cases (Family 3-I-2 and Family 18-II-1) experienced severe bleeding episodes (WHO bleeding score = 3) during surgery despite moderate thrombocytopenia (90 and $78 \times 10^9 \text{ L}^{-1}$, respectively). However, it is difficult to establish with certainty the role that *ACTN1* variants play in these severe episodes. These data highlight the need to carefully assess bleeding risk in *ACTN1*-RT patients as a precautionary measure.

Our results are consistent with previous reports showing platelet macrocytosis in *ACTN1*-RT patients (Bottega et al., 2015; Faleschini et al., 2018; Guéguen et al., 2013; Kunishima et al., 2013). Nevertheless, MPD values were at the upper normal limit in seven of nine cases with rod domain *ACTN1* variants. Rod domain variant carriers showed identical platelet counts but reduced MPD values compared with non-rod domain *ACTN1* variant carriers. This observation suggests that *ACTN1*-RT diagnosis should also be considered for inherited thrombocytopenia patients with normal platelet size. The functional consequences of rod domain variants may be less severe than those of the non-rod domains. The different effects of rod and non-rod variants in structurally homologous *ACTN1* proteins, such as the lamin A/C, have been reported. Variants in the rod domain of lamin A/C cause dilated

cardiomyopathy and conduction system disease without skeletal myopathy, whereas variants that do not affect the α -helical rod domain cause more severe disease with muscular dystrophy (Fatkin et al., 1999). Perhaps variants in the AB and CaM domains directly alter AB and head-to-tail polymerization, whereas variants in the rod domain affect rigidity and flexibility, thus causing a milder defect (Golji, Collins, & Mofrad, 2009).

Assessing the blood smears of ACTN1-RT patients, Faleschini et al. (2018) have recently described elongated and often curved platelets that sometimes had typical features of barbell-shaped proplatelets, which were not observed in healthy subjects. Such atypical platelets were not observed in our patients. However, blood smears in our study were prepared with EDTA anticoagulated blood, while the blood smears assessed by Faleschini et al. were prepared with non-anticoagulated blood.

This report of 11 new variants and 20 new pedigrees provides significant insight into the mechanisms of ACTN1-RT and highlights the high frequency of congenital ACTN1 variants as a cause of inherited thrombocytopenia. The rod domain, like the other functional domains of ACTN1, may harbor variants resulting in actin disorganization in vitro and thrombocytopenia with normal platelet size in most cases. The ACTN1 gene should be analyzed in cases of constitutional thrombocytopenia with normal or increased platelet size.

ACKNOWLEDGEMENTS

The authors thank Noémie Saut for performing genetic analyses, Sonia Poirault Chassac for performing immunofluorescence image analyses, Odile Fenneteau for helpful discussions, and Olivier René and Sylvie Binard for technical assistance. The authors also thank the patients and their families for their participation in the study. The study was funded in part by the “Département de la Recherche Clinique et du Développement (DRCD), Assistance Publique-Hôpitaux de Paris” (ID No.: P070110), the “Fondation pour la Recherche Médicale” (Grant to P. S.: FDM20150633607) and the French Foundation for Rare Diseases (Grant WES 2012-2001).

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

A. V. performed clinical and biological characterization of patients, analyzed the data, and wrote the paper. P. S. and M. P. designed and performed experiments (mutagenesis, immunofluorescence in CHO cells), analyzed the data, and wrote the paper. S. K. interpreted the data and revised the manuscript. M.F. H.-R. performed clinical and biological characterization of patients and analyzed the data. A. R. performed the structure analysis. ACTN1 study coinvestigators recruited the patients and collected clinical data. N. S. and M. C. A. supervised the study and wrote the paper.

ORCID

Anne Vincenot  <http://orcid.org/0000-0001-7629-5982>

Paul Saultier  <http://orcid.org/0000-0002-6327-0898>

Shinji Kunishima  <http://orcid.org/0000-0001-9212-0082>

Marjorie Poggi  <http://orcid.org/0000-0001-6331-9682>

Alain Roussel  <http://orcid.org/0000-0002-9831-3261>

Marie-Christine Alessi  <http://orcid.org/0000-0003-3927-5792>

REFERENCES

- Bottega, R., Marconi, C., Faleschini, M., Baj, G., Cagioni, C., Pecci, A., ... Noris, P. (2015). ACTN1-related thrombocytopenia: Identification of novel families for phenotypic characterization. *Blood*, 125(5), 869–872. <https://doi.org/10.1182/blood-2014-08-594531>
- Boutroux, H., David, B., Guéguen, P., Frange, P., Vincenot, A., Leverger, G., & Favier, R. (2017). ACTN1-related Macrothrombocytopenia: A novel entity in the progressing field of pediatric thrombocytopenia. *Journal of Pediatric Hematology/Oncology*, 39(8), e515–e518. <https://doi.org/10.1097/MPH.0000000000000885>
- Burkhardt, J. M., Vaudel, M., Gambaryan, S., Radau, S., Walter, U., Martens, L., ... Zahedi, R. P. (2012). The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. *Blood*, 120(15), e73–e82. <https://doi.org/10.1182/blood-2012-04-416594>
- Chakravarty, D., Chakraborti, S., & Chakraborti, P. (2015). Flexibility in the N-terminal actin-binding domain: Clues from in silico mutations and molecular dynamics. *Proteins*, 83(4), 696–710. <https://doi.org/10.1002/prot.24767>
- Djinovic-Carugo, K., Gautel, M., Ylännä, J., & Young, P. (2002). The spectrin repeat: A structural platform for cytoskeletal protein assemblies. *FEBS Letters*, 513(1), 119–123.
- Faleschini, M., Melazzini, F., Marconi, C., Giangregorio, T., Pippucci, T., Cigalini, E., ... Noris, P. (2018). ACTN1 mutations lead to a benign form of platelet macrocytosis not always associated with thrombocytopenia. *British Journal of Haematology*, 183(2), 276–288. <https://doi.org/10.1111/bjh.15531>
- Fatkin, D., MacRae, C., Sasaki, T., Wolff, M. R., Porcu, M., Frenneaux, M., ... McDonough, B. (1999). Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. *The New England Journal of Medicine*, 341(23), 1715–1724. <https://doi.org/10.1056/NEJM199912023412302>
- Foley, K. S., & Young, P. W. (2013). An analysis of splicing, actin-binding properties, heterodimerization and molecular interactions of the non-muscle α -actinins. *The Biochemical Journal*, 452(3), 477–488. <https://doi.org/10.1042/BJ20121824>
- Gache, Y., Landon, F., & Olomucki, A. (1984). Polymorphism of alpha-actinin from human blood platelets. Homodimeric and heterodimeric forms. *European Journal of Biochemistry*, 141(1), 57–61.
- Gimona, M., & Mital, R. (1998). The single CH domain of calponin is neither sufficient nor necessary for F-actin binding. *Journal of Cell Science*, 111(Pt 13), 1813–1821.
- Golji, J., Collins, R., & Mofrad, M. R. K. (2009). Molecular mechanics of the alpha-actinin rod domain: Bending, torsional, and extensional behavior. *PLoS Computational Biology*, 5(5), e1000389. <https://doi.org/10.1371/journal.pcbi.1000389>
- Guéguen, P., Rouault, K., Chen, J.-M., Raguénès, O., Fichou, Y., Hardy, E., ... Férec, C. (2013). A missense mutation in the alpha-actinin 1 gene (ACTN1) is the cause of autosomal dominant macrothrombocytopenia in a large French family. *PLoS One*, 8(9), e74728. <https://doi.org/10.1371/journal.pone.0074728>
- Kaplan, J. M., Kim, S. H., North, K. N., Rennke, H., Correia, L. A., Tong, H. Q., ... Pollak, M. R. (2000). Mutations in ACTN4, encoding

- alpha-actinin-4, cause familial focal segmental glomerulosclerosis. *Nature Genetics*, 24(3), 251–256. <https://doi.org/10.1038/73456>.
- Kircher, M., Witten, D. M., Jain, P., O’Roak, B. J., Cooper, G. M., & Shendure, J. (2014). A general framework for estimating the relative pathogenicity of human genetic variants. *Nature Genetics*, 46(3), 310–315. <https://doi.org/10.1038/ng.2892>
- Kos, C. H., Le, T. C., Sinha, S., Henderson, J. M., Kim, S. H., Sugimoto, H., ... Pollak, M. R. (2003). Mice deficient in alpha-actinin-4 have severe glomerular disease. *The Journal of Clinical Investigation*, 111(11), 1683–1690. <https://doi.org/10.1172/JCI17988>
- Kunishima, S., Okuno, Y., Yoshida, K., Shiraishi, Y., Sanada, M., Muramatsu, H., ... Ogawa, S. (2013). ACTN1 mutations cause congenital macrothrombocytopenia. *American Journal of Human Genetics*, 92(3), 431–438. <https://doi.org/10.1016/j.ajhg.2013.01.015>
- Murphy, A. C. H., Lindsay, A. J., McCaffrey, M. W., Djinić-Carugo, K., & Young, P. W. (2016). Congenital macrothrombocytopenia-linked mutations in the actin-binding domain of α -actinin-1 enhance F-actin association. *FEBS Letters*, 590(6), 685–695. <https://doi.org/10.1002/1873-3468.12101>
- Nurden, A. T., Freson, K., & Seligsohn, U. (2012). Inherited platelet disorders. *Haemophilia*, 18(Suppl 4), 154–160. <https://doi.org/10.1111/j.1365-2516.2012.02856.x>
- Ribeiro, E., Pinotsis, N., Ghisleni, A., Salmazo, A., Konarev, P., Kostan, J., ... Djinić-Carugo, K. (2014). The structure and regulation of human muscle α -actinin. *Cell*, 159(6), 1447–1460. <https://doi.org/10.1016/j.cell.2014.10.056>
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., ... ACMG Laboratory Quality Assurance Committee (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*, 17(5), 405–424. <https://doi.org/10.1038/gim.2015.30>
- Saposnik, B., Binard, S., Fenneteau, O., Nurden, A., Nurden, P., Hurtaud-Roux, M.-F., ... French MYH9 network (2014). Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders. *Molecular Genetics and Genomic Medicine*, 2(4), 297–312. <https://doi.org/10.1002/mgg3.68>
- Saultier, P., Vidal, L., Canault, M., Bernot, D., Falaise, C., Pouymayou, C., ... Alessi, M.-C. (2017). Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: Ultrastructural and pathogenic features. *Haematologica*, 102(6), 1006–1016. <https://doi.org/10.3324/haematol.2016.153577>
- Sjöblom, B., Salmazo, A., & Djinić-Carugo, K. (2008). Alpha-actinin structure and regulation. *Cellular and Molecular Life Sciences*, 65(17), 2688–2701. <https://doi.org/10.1007/s00018-008-8080-8>
- Westbury, S. K., Shoemark, D. K., & Mumford, A. D. (2017). ACTN1 variants associated with thrombocytopenia. *Platelets*, 28(6), 625–627. <https://doi.org/10.1080/09537104.2017.1356455>
- Westbury, S. K., Turro, E., Greene, D., Lentaigne, C., Kelly, A. M., Bariana, T. K., ... BRIDGE-BPD Consortium (2015). Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. *Genome Medicine*, 7(1), 36. <https://doi.org/10.1186/s13073-015-0151-5>
- Yasutomi, M., Kunishima, S., Okazaki, S., Tanizawa, A., Tsuchida, S., & Ohshima, Y. (2016). ACTN1 rod domain mutation associated with congenital macrothrombocytopenia. *Annals of Hematology*, 95(1), 141–144. <https://doi.org/10.1007/s00277-015-2517-6>

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Vincenot A, Saultier P, Kunishima S, et al. Novel ACTN1 variants in cases of thrombocytopenia. *Human Mutation*. 2019;40:2258–2269. <https://doi.org/10.1002/humu.23840>

APPENDIX A

ACTN1 STUDY CO-INVESTIGATORS

Christine Biron-Andreani,¹ Jean-François Claisse,² Rémy Duléry,^{3,4} Eric Durot,⁵ Mathieu Fiore,⁶ Rémi Favier,⁷ Pierre Fenaux,^{8,9} Felipe Guerrero,^{10,11} Véronique Le Cam-Duchez,¹² Elisabeth Mazoyer,¹³ Stéphanie Muller,¹⁴ Bénédicte Neven,¹⁵ Catherine Pouymayou,¹⁶ Bruno Royer,¹⁷ Pierre Sie,^{10,18} Sandrine Thouvenin,¹⁹ Catherine Trichet,²⁰ Nathalie Trillot²¹ and Karima Yakouben²²

¹Laboratory of Hematology, Regional Center for Hemophilia Treatment, University Hospital of Montpellier, Montpellier, France

²Laboratory of Hematology, Center of Human Biology, University Hospital of Amiens-Picardie, Amiens, France

³CHU Saint Antoine, Hematology Department, APHP, Paris, France

⁴Pierre and Marie Curie University, Paris, France

⁵Clinical Hematology, University Hospital of Reims, Reims, France

⁶Laboratory of Hematology, University Hospital of Bordeaux, Bordeaux, France

⁷Biological Hematology and National Reference Center for Inherited Platelet Disorders, CHU Armand Trousseau, Paris, France

⁸Hematology Seniors Service, CHU Saint Louis, Paris, France

⁹Paris 7 University, Paris, France

¹⁰CHU Toulouse, Biological Hematology, Toulouse, France

¹¹CHU Toulouse, National Reference Center for Inherited Platelet Disorders, Toulouse, France

¹²Rouen University Hospital, Department of Biological Hematology, F76000 Rouen, France

¹³Hôpital Avicenne, Biological Hematology, Bobigny, France

¹⁴CH Rambouillet, Pediatrics, Rambouillet, France

¹⁵CHU Necker-Enfants Malades, Immunological and Pediatric Hematology, Paris, France

¹⁶CHU Timone, National Reference Center for Inherited Platelet Disorders, Marseille, France

¹⁷CHU Amiens, Clinical Hematology and Cellular Therapy, Amiens, France

¹⁸Université Paul Sabatier, Toulouse, France

¹⁹Pediatric Hematology, University Hospital of Saint-Etienne, Saint-Etienne, France

²⁰Hematology Department, HUPNVS, APHP, Clichy, France

²¹CHU Lille, Hematology and Transfusion Institute, F-59000 Lille, France

²²CHU Robert Debré, Department of Pediatric Clinical Hematology and Immunology, APHP, Paris, France